Readoutin 45d
MoonLake Immunotherapeutics AG — Sonelokimab
Phase 3 primary completion: Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response.
- Date
- Jan 2027
- Type
- Readout
- Indication
- Arthritis, Psoriatic